Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis

Laura Geraldino-Pardilla, Cesare Russo, Jeremy Sokolove, William H. Robinson, Afshin Zartoshti, Jenny V. Van Eyk, Justyna Fert-Bober, Joao Lima, Jon T. Giles, Joan M. Bathon

Research output: Contribution to journalArticle

Abstract

Objective. High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods. Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance- derived LV measures were evaluated. High ACPA level was defined as ≥ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results. In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P<0.05). In contrast, higher levels of anticitrullinated biglycan247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P<0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anticitrullinated fibrinogen556-575 and anti-citrullinated vimentin58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P<0.05), but no association with biglycan was found. Conclusion. Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.

Original languageEnglish (US)
Article numberkew436
Pages (from-to)534-540
Number of pages7
JournalRheumatology (United Kingdom)
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Left Ventricular Function
Rheumatoid Arthritis
Vimentin
Peptides
Antibodies
Fibrinogen
Proteins
Heart Failure
Biglycan
Three-Dimensional Echocardiography
Protein Transport
Arthritis
Cardiovascular Diseases
Magnetic Resonance Spectroscopy
Phenotype
Serum

Keywords

  • Anti-citrullinated peptide antibody (ACPA)
  • CVD
  • RA
  • Ventricular mass

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Geraldino-Pardilla, L., Russo, C., Sokolove, J., Robinson, W. H., Zartoshti, A., Van Eyk, J. V., ... Bathon, J. M. (2017). Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (United Kingdom), 56(4), 534-540. [kew436]. https://doi.org/10.1093/rheumatology/kew436

Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. / Geraldino-Pardilla, Laura; Russo, Cesare; Sokolove, Jeremy; Robinson, William H.; Zartoshti, Afshin; Van Eyk, Jenny V.; Fert-Bober, Justyna; Lima, Joao; Giles, Jon T.; Bathon, Joan M.

In: Rheumatology (United Kingdom), Vol. 56, No. 4, kew436, 01.04.2017, p. 534-540.

Research output: Contribution to journalArticle

Geraldino-Pardilla, L, Russo, C, Sokolove, J, Robinson, WH, Zartoshti, A, Van Eyk, JV, Fert-Bober, J, Lima, J, Giles, JT & Bathon, JM 2017, 'Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis', Rheumatology (United Kingdom), vol. 56, no. 4, kew436, pp. 534-540. https://doi.org/10.1093/rheumatology/kew436
Geraldino-Pardilla, Laura ; Russo, Cesare ; Sokolove, Jeremy ; Robinson, William H. ; Zartoshti, Afshin ; Van Eyk, Jenny V. ; Fert-Bober, Justyna ; Lima, Joao ; Giles, Jon T. ; Bathon, Joan M. / Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. In: Rheumatology (United Kingdom). 2017 ; Vol. 56, No. 4. pp. 534-540.
@article{b88adc0737ca4a77b973aa9cac663087,
title = "Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis",
abstract = "Objective. High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods. Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance- derived LV measures were evaluated. High ACPA level was defined as ≥ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results. In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6{\%} higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P<0.05). In contrast, higher levels of anticitrullinated biglycan247-266 were associated with a 13{\%} lower adjusted mean LVMI compared with lower levels (P<0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anticitrullinated fibrinogen556-575 and anti-citrullinated vimentin58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15{\%}, respectively; P<0.05), but no association with biglycan was found. Conclusion. Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.",
keywords = "Anti-citrullinated peptide antibody (ACPA), CVD, RA, Ventricular mass",
author = "Laura Geraldino-Pardilla and Cesare Russo and Jeremy Sokolove and Robinson, {William H.} and Afshin Zartoshti and {Van Eyk}, {Jenny V.} and Justyna Fert-Bober and Joao Lima and Giles, {Jon T.} and Bathon, {Joan M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1093/rheumatology/kew436",
language = "English (US)",
volume = "56",
pages = "534--540",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis

AU - Geraldino-Pardilla, Laura

AU - Russo, Cesare

AU - Sokolove, Jeremy

AU - Robinson, William H.

AU - Zartoshti, Afshin

AU - Van Eyk, Jenny V.

AU - Fert-Bober, Justyna

AU - Lima, Joao

AU - Giles, Jon T.

AU - Bathon, Joan M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective. High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods. Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance- derived LV measures were evaluated. High ACPA level was defined as ≥ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results. In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P<0.05). In contrast, higher levels of anticitrullinated biglycan247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P<0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anticitrullinated fibrinogen556-575 and anti-citrullinated vimentin58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P<0.05), but no association with biglycan was found. Conclusion. Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.

AB - Objective. High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods. Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance- derived LV measures were evaluated. High ACPA level was defined as ≥ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results. In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P<0.05). In contrast, higher levels of anticitrullinated biglycan247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P<0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anticitrullinated fibrinogen556-575 and anti-citrullinated vimentin58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P<0.05), but no association with biglycan was found. Conclusion. Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.

KW - Anti-citrullinated peptide antibody (ACPA)

KW - CVD

KW - RA

KW - Ventricular mass

UR - http://www.scopus.com/inward/record.url?scp=85017276374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017276374&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kew436

DO - 10.1093/rheumatology/kew436

M3 - Article

VL - 56

SP - 534

EP - 540

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 4

M1 - kew436

ER -